LymphDetect™ Head & Neck
Head and Neck Cancer (Post-operative recurrence risk assessment)
Key Facts
About Droplet Biosciences
Droplet Biosciences is an early-stage diagnostics company developing a proprietary platform to analyze post-surgical lymphatic fluid, a previously inaccessible biofluid, for the detection of minimal residual disease. The company's lead product, LymphDetect™ Head & Neck, is a CLIA test that detects ctDNA in drain fluid from head and neck cancer surgeries, aiming to provide superior sensitivity and earlier recurrence risk assessment than blood-based tests. By leveraging the lymphatic system's proximity to the tumor site, Droplet seeks to enable more timely and precise adjuvant treatment decisions, potentially improving patient outcomes. The company is collaborating with leading medical centers and has announced a technology partnership with NVIDIA to accelerate its bioinformatics pipeline.
View full company profile